Polymeric protective agents for nanoparticles in drug delivery and targeting

Mogoşanu, George Dan; Grumezescu, Alexandru Mihai; Bejenaru, Cornelia; Bejenaru, Ludovic Everard

doi:10.1016/j.ijpharm.2016.03.014

Cited by 59 publications

(29 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological molecules tend to adsorb on the surface of the particles upon intravenous administration, reducing its ability to damage the erythrocytes in the bloodstream . Moreover, the opsonization by serum or plasma proteins, known as opsonize, might also reduce the damage to the erythrocytes caused by the nanoparticles on blood …”

Section: Resultsmentioning

confidence: 99%

Self‐aggregated nanoparticles of N‐dodecyl,N′‐glycidyl(chitosan) as pH‐responsive drug delivery systems for quercetin

Pedro

Pereira

Goycoolea

et al. 2017

J of Applied Polymer Sci

View full text Add to dashboard Cite

In this study, pH‐responsive amphiphilic chitosan (CS) nanoparticles were used to encapsulate quercetin (QCT) for sustained release in cancer therapy. The novel CS derivatives were obtained by synthesis with 2,3‐epoxy‐1‐propanol, also known as glycidol, followed by acylation with dodecyl aldehyde. Characterization was performed by spectroscopic, viscosimetric, and size‐determination methods. Critical aggregation concentration, morphology, entrapment efficiency, drug release profile, cytotoxicity, and hemocompatibility studies were also carried out. The average size distribution of the self‐assembling nanoparticles measured by dynamic light scattering ranged from 140 to 300 nm. In vitro QCT release and Korsmeyer–Peppas model indicated that pH had a major role in drug release. Cytotoxicity assessments indicated that the nanoparticles were non‐cytotoxic. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay further revealed that QCT‐loaded nanoparticles could inhibit MCF‐7 cell growth. In vitro erythrocyte‐induced hemolysis indicated the good hemocompatibility of the nanoparticles. These results suggest that the synthesized copolymers might be potential carriers for hydrophobic drugs in cancer therapy. © 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2018, 135, 45678.

show abstract

Section: Resultsmentioning

confidence: 99%

Self‐aggregated nanoparticles of N‐dodecyl,N′‐glycidyl(chitosan) as pH‐responsive drug delivery systems for quercetin

Pedro

Pereira

Goycoolea

et al. 2017

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…Giant amphiphile-based formulations surpassing or matching the antitumoral activity of the free DTX formulation were identified in all cases, overcoming the DTX water solubility problems. The proposed self-assembled nanocarriers are further intended to be biocompatible, to have a low propensity to undergo protein serum adsorption and to be compatible with the incorporation of targeting moieties for tumor-specific drug delivery, by virtue of exposing cyclooligosaccharidic βCD units at their surface (Mogosanu et al, 2016). This should allow them to bypass healthy cells, thus reducing the side-effects associated with DTX treatment.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells

et al. 2017

View full text Add to dashboard Cite

Giant amphiphiles encompassing a hydrophilic β-cyclodextrin (βCD) component and a hydrophobic calix[4]arene (CA4) module undergo self-assembly in aqueous media to afford core-shell nanospheres or nanocapsules, depending on the nanoprecipitation protocol, with high docetaxel (DTX) loading capacity. The blank and loaded nanoparticles have been fully characterized by dynamic light scattering (DLS), ζ-potential measurements and cryo-transmission electron microscopy (cryo-TEM). The data are compatible with the distribution of the drug between the nanoparticle core and the shell, where it is probably anchored by inclusion of the DTX aromatic moieties in βCD cavities. Indeed, the release kinetics profiles evidenced an initial fast release of the drug, which likely accounts for the fraction hosted on the surface, followed by a slow and sustained release rate, corresponding to diffusion of DTX in the core, which can be finely tuned by modification of the giant amphiphile chemical structure. The ability of the docetaxel-loaded nanoparticles to induce cellular death in different prostate (human LnCap and PC3) and glioblastoma (human U87 and rat C6) cells was also explored. Giant amphiphile-based DTX formulations surpassing or matching the antitumoral activity of the free DTX formulation were identified in all cases with no need to employ any organic co-solvent, thus overcoming the DTX water solubility problems. Moreover, the presence of the βCD shell at the surface of the assemblies is intended to impart stealth properties against serum proteins while permitting nanoparticle surface decoration by supramolecular approaches, paving the way for a new generation of molecularly well-defined antitumoral drug delivery systems with improved specificity and efficiency. Altogether, the results provide a proof of concept of the suitability of the approach based on βCD-CA4 giant amphiphiles to access DTX carriers with tunable properties.

show abstract

“…Target agents can identify and combine specifically with molecules that are only expressed, or are overexpressed, in tumor cells compared with non-tumor tissue, thereby reducing the side effects of chemotherapy. 62 For example, the epidermal growth factor receptor (EGFR) is overexpressed or abnormally expressed in many solid tumors (e.g., non-small cell lung cancer, prostate cancer, breast cancer and melanoma). [63][64][65][66][67] Song et al designed GE11-modified liposomes that can combine specifically and effectively with non-small cell lung cancer cells overexpressing EGFR.…”

Section: Nanoparticles As Drug Carriersmentioning

confidence: 99%

Recent developments in nanomedicine for melanoma treatment

Tang

Hou

Yang

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Melanoma is a most aggressive skin cancer with limited therapeutic options and its incidence is increasing rapidly in recent years. The discovery and application of new targeted therapy agents have shown significant benefits. However, adverse side-effects and resistance to chemotherapy remain formidable challenges in the clinical treatment of malignant melanoma. Nanotherapeutics offers an important prospect of overcoming these drawbacks. The anti-tumoral applications of nanomedicine are varied, including those in chemotherapy, RNA interference, photothermal therapy, and photodynamic therapy. Furthermore, nanomedicine allows delivery of the effector structures into the tumor site via passive or active targeting, thereby allowing increased therapeutic specificity and reduced side effects. In this review, we summarize the latest developments in the application of nanocarrier-mediated targeted drug delivery to melanoma and nanomedicine-related clinical trials in melanoma treatment. We also discuss existing problems and opportunities for future developments, providing direction and new thoughts for further studies.

show abstract

Polymeric protective agents for nanoparticles in drug delivery and targeting

Cited by 59 publications

References 195 publications

Self‐aggregated nanoparticles of N‐dodecyl,N′‐glycidyl(chitosan) as pH‐responsive drug delivery systems for quercetin

Self‐aggregated nanoparticles of N‐dodecyl,N′‐glycidyl(chitosan) as pH‐responsive drug delivery systems for quercetin

Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells

Recent developments in nanomedicine for melanoma treatment

Contact Info

Product

Resources

About